Renal effects of Saxagliptin and Linagliptin in diabetic nephropathy: A randomized, double-blind, head to head study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006340

Enrollment

Unknown

Registered

2015-04-28

Start date

2015-05-07

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Interventions

Saxagliptin group:with Saxagliptin treatment

Linagliptin group:with Linagliptin treatment

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Outpatients in line with diagnostic criteria for type 2 diabetes; 2. Urinary albumin/creatinine ratio (ACR) not less than 30 mg/g; 3. GFR not less than 60 ml/min; 4. Combined with diet, exercise and the current regimen, blood glucose is still poorly controlled.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes or secondary diabetes; 2. Gestational diabetes, lactational diabetes and diabetes planning to be pregnant; 3. Urinary tract infection or other serious infections; 4. With other non-diabetic kidney disease; 5. DPP-4 inhibitors or GLP-1 agonist medication history within a month; 6. Insulin medication history; 7. With resistant hypertension; 8. ACEI or ARB medication history; 9. Severe renal impairment (creatinine clearance150 umol/L); 10. Severely impaired liver function (serum alanine aminotransferase or aspartate aminotransferase more than 3 times of the upper limit); 11. History of acute diabetic complications, history of trauma and history of surgery within the past month; 12. With any major psychiatric disorder; 13. Hypersusceptibility to the test medicine or with allergies; 14. Participating in other clinical trials; 15. Alcohol or psychoactive substance abusers and addicts; 16. According to the judgment of researchers, it will reduce the possibility to participate the study or make the participating more complex, for example, change the work or living environment frequently.

Design outcomes

Primary

Measure	Time frame
Urinary albumin creatinine ratio;Transferrin;N- acetyl-Beta-D- glucosidase;Beta 2-microglobulin;	—

Secondary

Measure	Time frame
Weight;Blood pressure;Fasting blood glucose;Glycolated hemoglobin;Blood lipid;	—

Countries

China

Contacts

Public ContactZhongming Wu

wuzhongming@tijmu.edu.com+86 13672093136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026